A de novo germline APC mutation (3927del5) in a patient with familial adenomatous polyposis: Case report and literature review

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 315-323

  Zeichner, Simon B ^a   Raj, Naveen ^a   Cusnir, Mike ^a   Francavilla, Michael ^a   Hirzel, Alicia ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Colon cancer; Familial adenomatous polyposis; FAP; Sporadic mutation

Indexed keywords

AMINO ACID; APC PROTEIN; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER RISK; CASE REPORT; COLON ADENOCARCINOMA; COLON POLYP; COLON RESECTION; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; ENDOSCOPY; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; FEMALE; GENE DELETION; GENETIC SCREENING; GERM LINE; HISPANIC; HUMAN; PHENOTYPE; RECTUM POLYP; RISK ASSESSMENT; SIGMOID; SIGMOIDOSCOPY; SOUTHERN BLOTTING; TUMOR BIOPSY;

EID: 84866076504     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S10178     Document Type: Article

References (62)

1. Wennstrom J, Pierce ER, McKusick VA. Hereditary benign and malignant lesions of the large bowel. Cancer. 1974;34(Suppl 3):850-7.
2. Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med. 1995;46:371-9.
3. Laurent-Puig P, Béroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1998; 26:269-70.
4. Moisio AL, Järvinen H, Peltomäki P. Genetic and clinical characterisation of familial adenomatous polyposis: a population based study. Gut. 2002;50(6): 845-50.
5. Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med. 1999;5(9): 1071-5.
6. Järvinen HJ, Peltomäki P. The complex genotype-phenotype relationship in familial adenomatous polyposis. Eur J Gastroenterol Hepatol. 2004;16(1): 5-8.
7. Giardiello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. Gastroenterology. 1994;106(6):1542-7.
8. Comprehensive COLARIS AP: APC analysis and MYH mutation panel. myriad genetic laboratories. Accessed Mar 18, 2012.
9. Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology. 1995;109(5):1685-99.
10. Papadopoulos N, Nicolaides NC, Liu B, et al. Mutations of GTBP in genetically unstable cells. Science. 1995;268(5219):1915-7.
11. Baker SM, Bronner CE, Zhang L, et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell. 1995;82(2):309-19.
12. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263(5153):1625-9.
13. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22): 5248-57.
14. Michalopoulos NV, Saetta A, Lazaris ACh, Voutsinas G, Davaris PS. Detection of genetic abnormalities in neoplasms from Greek patients with FAP. Eur J Surg Oncol. 2003;29(1):38-43.
15. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science. 1997; 275(5307):1784-7.
16. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275(5307):1787-90.
17. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18(9):1967-79.
18. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111(2):241-50.
19. Shih IM, Wang TL, Traverso G, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci U S A. 2001;98(5):2640-5.
20. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362(9379):205-9.
21. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4:343-64.
22. Facts about Genome Sequencing, Human genome project: united states department of energy. Accessed Jul 26, 2012.
23. Hadjisavvas A, Papasavva T, Loizidou M, Malas S, Potamitis G, Christodoulou C, et al. Novel germline mutations in the APC gene of Cypriot patients with familial and sporadic adenomatous polyposis. Clin Genet. 2006;69(5):404-9.
24. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1993;2(6):425-34.
25. Lynch HT, Tinley ST, Shaw TG, Lynch JF, Howe JR, Attard TM. Challenging colonic polyposis pedigrees: differential diagnosis, surveillance, and management concerns. Cancer Genet Cytogenet. 2004;148(2): 104-17.
26. Aretz S, Uhlhaas S, Caspari R, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J of Hum Genet. 2004;12(1):52-8.
27. Armstrong JG, Davies DR, Guy SP, Frayling IM, Evans DG. APC mutations in familial adenomatous polyposis families in the Northwest of England. Hum Mutat. 1997;10(5):376-80.
28. Nagase H, Miyoshi Y, Horii A, et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res. 1992;52(14):4055-7.
29. Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995;4(3): 337-40.
30. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet. 1998;62(6): 129-1301.
31. Touriño R, Conde-Freire R, Cabezas-Agrícola JM, et al. Value of the congenital hypertrophy of the retinal pigment epithelium in the diagnosis of familial adenomatous polyposis. Int Ophthalmol. 2004;25(2):101-12.
32. Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc. 2002;55(3):342-7.
33. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on Feb 20, 1996. J Clin Oncol. 1996; 14(5):1730-6; discussion 1737-40.
34. NCCN colorectal cancer screening practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park). 1999;13:152.
35. Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology. 2005;128(6):1696-716.
36. American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195-7.
37. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer. 1995;76(12):2427-33.
38. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385-98.
39. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2(1):43-55.
40. Russell AM, Zhang J, Luz J, et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer. 2006; 118(8):1937-40.
41. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003;348(9):791-9.
42. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology. 2004;127(1):9-16.
43. Balaguer F, Castellví-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, populationbased study. Clin Gastroenterol Hepatol. 2007;5(3):379-87.
44. Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137(6):1883-1886. Epub Oct 29, 2009.
45. Theodoratou E, Campbell H, Tenesa A, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer. 2010;103(12):1875-84. Epub Nov 9, 2010.
46. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6): 1976-85. e1-10. Epub Sep 2, 2009.
47. Hamilton SR, Bussey HJ, Mendelsohn G, et al. Ileal adenomas after colectomy in nine patients with adenomatous polyposis coli/Gardner's syndrome. Gastroenterology. 1979;77(6):1252-7.
48. Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1(8595):1149-51.
49. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg. 1998;85(6):742-50.
50. Primrose JN, Quirke P, Johnston D. Carcinoma of the ileostomy in a patient with familial adenomatous polyposis. Br J Surg. 1988;75:384.
51. Parc YR, Olschwang S, Desaint B, et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg. 2001;233:360.
52. Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol. 2008;15(9): 2439-50.
53. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. 1998;90(14):1039-71.
54. Heiskanen I, Kellokumpu I, Järvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy. 1999;31(6):412-6.
55. Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol. 2004;99(4):681-6.
56. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992;43(6):1023-5.
57. Nieuwenhuis MH, Mathus-Vliegen LM, Slors FJ, et al. Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2007;5(3):374-8.
58. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-52.
59. Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010;105(6):1437-43.
60. Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002;122(3):641-5.
61. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet. 1998;62(6): 1290-301.
62. Björk J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology. 2001;121(5):1127-35.